ChemGenex Pharmaceuticals Ltd. (CXSP-NASDAQ) and (ASX-CXS)
Interview with: Greg Collier, Ph.D., CEO and Managing Director
Business News, Financial News, Stocks, Money & Investment Ideas, CEO Interview
and Information on their understanding of the genetic basis of diseases such as diabetes, depression, inflammation and cancer to discover and develop unique personalized medicine solutions to improve patient outcomes.

 

Cover Story

CEOCFO Current Issue

Cover Story Archives

Private Equity Review

CEOCFO Interview Index

Future Features

Analyst Interviews

Corporate Financials

Contact & Ordering

This is a printer friendly page!

ChemGenex Pharmaceuticals’ Ceflatonin® is very exciting because in clinical trials it has shown to be effective in treating myeloid leukemia (CML) patients that are developing resistance to tyrosine kinase inhibitors such as Gleevec®

wpe4.jpg (3626 bytes)

Healthcare
Pharmaceuticals
(CXSP-NASDAQ) and (ASX-CXS)

ChemGenex Pharmaceuticals Ltd.


wpeA.jpg (7436 bytes)

Greg Collier, Ph.D.
CEO and Managing Director

Interview conducted by:
Lynn Fosse, Senior Editor
CEOCFOinterviews.com
October 6, 2005.



To order the complete October 20, 2005 Issue of CEOCFOinterviews.com left click below for our forms:

Purchase NOW!

There is a $5.00 charge for each current issue!
You will be emailed an invoice for Credit Card payment, followed by your ordered Current Issue !


disclaimers

Any reproduction or further distribution of this article without the express written consent of CEOCFOinterviews.com is prohibited.

“Our program with Quinamed® and prostate cancer is one of the very few examples that are actually in the clinic using the generic variability as a way to improve therapeutic outcome.” - Greg Collier, Ph.D.

Newsflash!

To view Releases highlight & left click on the company name!

 

ceocfointerviews.com does not purchase or make
recommendation on stocks based on the interviews published.

.